The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...
According to Nova One Advisor, the global genomics data analysis market size is calculated at USD 7.91 billion in 2025 and is ...
The United States Tumor Profiling Market is projected to surge from US$ 3.41 billion in 2024 to US$ 7.44 billion by 2033, ...
The Chinese DNA sequencing market is expanding rapidly due to rising demand for precision medicine, technological advancements, and government investments. Key opportunities lie in oncology ...
DNA sequencing alone misses many disease dynamics. Researchers are turning to epigenomic profiling, especially the biomarker ...
In a breakthrough that redefines both speed and clinical potential, a new world record for the fastest human whole genome ...
Overview of Epigenetics MarketThe global Epigenetics Market is valued at USD 2.56 Billion in 2024 and is projected to reach a value of USD 9.11 Billion by 2035 at a CAGR (Compound Annual Growth Rate) ...
For managed care organizations and health systems, the recommendations strongly advocated highly selective use of NGS. Routine, nonselective NGS for all sarcoma patients is not justified. Instead, ...
AI and accelerated computing are transforming the bio/pharmaceutical sector by addressing organizational, technological, and ...
New plate-based multiplexing unlocks ultra-high-sample and cell-throughput single cell analysis to empower a broad range of studies.
In this interview, we explore how single-cell technologies, automation and strategic partnerships are shaping the future of cancer immunotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback